Ensysce Biosciences, Inc. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported net loss was USD 2.19 million compared to USD 0.951107 million a year ago. Basic loss per share from continuing operations was USD 2.08 compared to USD 14.66 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.592 USD | +2.96% | +3.86% | -44.15% |
05-28 | Ensysce Biosciences Back in Compliance With Nasdaq | MT |
05-20 | Sector Update: Health Care Stocks Softer Late Afternoon | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-44.15% | 4.49M | |
+48.64% | 56.65B | |
-6.44% | 39.44B | |
+37.07% | 39.03B | |
+14.28% | 26.75B | |
-11.17% | 26.86B | |
-21.40% | 19.03B | |
+25.64% | 12.26B | |
+0.96% | 12.28B | |
+27.04% | 12.04B |
- Stock Market
- Equities
- ENSC Stock
- News Ensysce Biosciences, Inc.
- Ensysce Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023